Targeting GPX4 degradation through disulfiram: A novel mechanism for ferroptosis induction in leukemia cells DOI Creative Commons
Caixia Wang, Shunqing Wang

Cell investigation., Journal Year: 2024, Volume and Issue: 1(1), P. 100006 - 100006

Published: Dec. 5, 2024

Language: Английский

Increased Co-Expression of PD-L1 and CTLA-4 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation DOI Creative Commons
Cunte Chen,

Kangjie Qiu,

Jie Chen

et al.

ImmunoTargets and Therapy, Journal Year: 2025, Volume and Issue: Volume 14, P. 25 - 33

Published: Jan. 1, 2025

Our previous study has demonstrated that high expression of immune checkpoints (ICs) was significantly associated with adverse clinical outcomes in patients acute myeloid leukemia (AML). This aims to investigate the significance alteration IC co-expression for evaluating prognosis AML following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Quantitative real-time PCR (qRT-PCR) data bone marrow (BM) samples from 62 de novo patients, including 37 who received allo-HSCT and 25 chemotherapy only, were used prognostic analysis. High PD-1, PD-L1, PD-L2, CTLA-4, LAG-3 poor overall survival (OS) receiving allo-HSCT, while levels LAG-3, other than not correlated OS chemotherapy. Importantly, PD-L1/CTLA-4 best combination model predicting especially combined minimal residual disease (MRD). ICs BM related outcomes, increasing PD-L1 CTLA-4 might be one biomarkers predict AML.

Language: Английский

Citations

0

AGR, LMR and SIRI are the optimal combinations for risk stratification in advanced patients with non-small cell lung cancer following immune checkpoint blockers DOI

Yun Zhou,

Xia Liu,

Biwen Wu

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 149, P. 114215 - 114215

Published: Feb. 3, 2025

Language: Английский

Citations

0

Synergistic Effects of BET Inhibitors and Ferroptosis Inducers via Targeted Inhibition of the BRD4/c-Myc/NRF2 Pathway in AML DOI
Mengjun Zhong, Shuxin Zhong,

Kangjie Qiu

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177652 - 177652

Published: April 1, 2025

Language: Английский

Citations

0

Shikonin promotes ferroptosis though NSUN2-mediated m 5 C methylation modification of TFRC in acute myelocytic leukemia DOI Creative Commons
Shuyu Chen, Yiqun Huang, Yinhao Liu

et al.

Hematology, Journal Year: 2025, Volume and Issue: 30(1)

Published: April 24, 2025

Shikonin (SHK), extracted from the traditional Chinese herb Lithospermum erythrorhizon, demonstrates a wide range of pharmacological activities. This study aimed to explore role and underlying mechanisms 5-methylcytosine (m5C) RNA methyltransferase NOL1/NOP2/SUN domain (NSUN)2 in acute myelocytic leukemia (AML). To assess cell viability death, we employed Cell Counting Kit-8 propidium iodide staining. Ferroptosis-related markers were evaluated using commercial kits Western blot analysis. The m5C levels ferroptosis-associated mRNAs quantified by methylated immunoprecipitation (MeRIP)-qPCR. specific sites on transferrin receptor (TFRC) mRNA identified through dual-luciferase reporter assay, while interaction between NSUN2 TFRC was investigated (RIP). SHK vivo explored xenografted tumor model. Our findings revealed that significantly reduced induced death ferroptosis HL-60 NB4 cells. Notably, treatment led an upregulation expression. Inhibition reversed effects SHK, restoring reducing ferroptosis. Mechanistically, enhanced expression via m5C-dependent methylation. Overexpression similarly decreased increased ferroptosis, mitigated upon silencing TFRC. In vivo, effectively suppressed growth mice. summary, our demonstrated promoted AML modulating NSUN2-mediated methylation These provided novel insights into potential therapeutic strategies for AML.

Language: Английский

Citations

0

Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia DOI Creative Commons
Xiangbo Zeng, Dingrui Nie, Zhen Liu

et al.

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 12297 - 12309

Published: Nov. 1, 2024

T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disease with limited targeted therapy options. Overexpression of B-cell lymphoma/leukemia 11B frequently observed in T-ALL and contributes to leukemogenesis. Knockdown BCL11B inhibits cell proliferation induces apoptosis, making it potential therapeutic target. However, the clinical application siRNA therapies hindered by challenges such as poor delivery efficiency outcomes.

Language: Английский

Citations

1

Targeting GPX4 degradation through disulfiram: A novel mechanism for ferroptosis induction in leukemia cells DOI Creative Commons
Caixia Wang, Shunqing Wang

Cell investigation., Journal Year: 2024, Volume and Issue: 1(1), P. 100006 - 100006

Published: Dec. 5, 2024

Language: Английский

Citations

1